FDA action for BLA for bimekizumab for the treatment of adults with moderate to severe plaque psoriasis is now shifted to Q3 2023 – UCB
UCB, a global biopharmaceutical company,announced that the Biologics License Application (BLA) for bimekizumab for the treatment of adults with moderate to severe plaque psoriasis remains under review with the FDA. UCB previously communicated the FDA action was expected in Q2, 2023. UCB now anticipates the FDA action in Q3, 2023. There are no open Information Requests from the FDA regarding […]
Recent Comments